Evaluation of Intrathecal Hyperbaric Bupivacaine With Dexmedetomidine in Adults Undergoing Perianal Surgery (DEX-BUP)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
-
Karachi, Pakistan
- Liaquat National Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients undergoing elective perianal surgery under spinal saddle block were included in the study.
- Age between 40-80 years
- ASA status I and II
Exclusion Criteria:
- Pregnant women
- Patient with coagulopathy
- Infection at or near the needle insertion site
- Allergy to the trial drug
- Patient with chronic pain
- Cognitive impairment
- Patient with known drug or substance abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dexemedetomidine
Experimental group received intrathecal dexmedetomidine 5 microgram added to 5 mg of 0.5% hyperbaric bupivacaine in dextrose injection
|
dexmedetomidine 5 microgram added to 5 mg of 0.5% hyperbaric bupivacaine in dextrose injection
|
|
Active Comparator: Hyperbaric bupivacaine
Active comparator had 5 mg of 0.5% hyperbaric bupivacaine in dextrose injection alone
|
5 mg of 0.5% hyperbaric bupivacaine in dextrose injection alone
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of analgesia
Time Frame: 0 hour to 4 hours
|
duration of analgesia was assessed from induction of anesthesia till patient discharge
|
0 hour to 4 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain score
Time Frame: Two hours post surgery till 24 hours
|
Pain will be assessed using Numeric Rating Scale (NRS) scale ranging from 0-10; 0 being no pain and 10 indicates the worst pain
|
Two hours post surgery till 24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
- Effects of Adding Intrathecal Dexmedetomidine to Hyperbaric Bupivacaine for Saddle Spinal Block in Adults Undergoing Peri-anal Surgeries
- Effect Of Dexmedetomidine Added To Intrathecal Hyperbaric Bupivacaine Versus Bupivacaine Alone On Mean Postoperative Analgesia After Spinal Saddle Block
- EFFECT OF ADDING DEXMEDETOMIDINE VERSUS FENTANYL TO INTRATHECAL HYPERBARIC BUPIVACAINE ON SPINAL BLOCK FOR INFRAUMBILICAL ELECTIVE SURGERIES
- Effects of intravenous dexmedetomidine on hyperbaric bupivacaine spinal anesthesia: A randomized study
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB-App#0792-2022-LNH-ERC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.